Literature DB >> 10554046

Basis of anti-infective therapy: pharmacokinetic-pharmacodynamic criteria and methodology for dual dosage individualisation.

A Sánchez-Navarro1, M M Sánchez Recio.   

Abstract

Antimicrobial therapy should be designed on the basis of microbiological, as well as pharmacokinetic, criteria; microbiological parameters provide information about the susceptibility of the pathogen responsible for the infectious process while pharmacokinetic parameters give information about the potential ability of the drug in question to reach and remain at the sites of infection in the body. Microbiological parameters such as the minimum inhibitory concentration, minimum bactericidal concentration, bacterial titre, bactericidal rate and 'post-antibiotic effect' (PAE) must be considered. Among the pharmacokinetic parameters, the maximum serum concentration at steady state (CmaxSS), area under the concentration-time curve (AUC) and length of time that the serum concentrations exceed a particular value are the most useful in this context. Different relationships between these parameters, known as efficacy indices, have been established to predict the potential efficacy of antibacterial therapy. Antimicrobial dosage individualisation should be based on the optimisation of the efficacy index that best correlates with patient response. It seems appropriate to establish the degree of correlation among the different efficacy indices and clinical response observed in patients by means of a correlation analysis. This type of analysis can be either retrospective or prospective and may be based on linear or maximum response models. Simulation of the plasma concentration curves obtained with the particular regimen administered offers a methodology which is easy to apply and provides the pharmacokinetic information necessary to calculate the different efficacy indices. Information about the susceptibility of the pathogen to the antibacterial in question and about the response to the treatment used is also necessary for the correlation analysis. This type of analysis determines which of the indices is best correlated with efficacy and, hence, is the index to be optimised when attempting to individualise antibacterial therapy for different situations.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10554046     DOI: 10.2165/00003088-199937040-00002

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  66 in total

1.  Mathematical examination of dual individualization principles (I): Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin.

Authors:  J J Schentag; D E Nix; M H Adelman
Journal:  DICP       Date:  1991-10

2.  Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis.

Authors:  A Forrest; S Chodosh; M A Amantea; D A Collins; J J Schentag
Journal:  J Antimicrob Chemother       Date:  1997-12       Impact factor: 5.790

3.  Extended least squares nonlinear regression: a possible solution to the "choice of weights" problem in analysis of individual pharmacokinetic data.

Authors:  C C Peck; S L Beal; L B Sheiner; A I Nichols
Journal:  J Pharmacokinet Biopharm       Date:  1984-10

Review 4.  Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

Authors:  N H Holford; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

5.  Pharmacokinetics of three newer quinolones in pregnant and lactating women.

Authors:  H Giamarellou; E Kolokythas; G Petrikkos; J Gazis; D Aravantinos; P Sfikakis
Journal:  Am J Med       Date:  1989-11-30       Impact factor: 4.965

6.  Bioavailability and pharmacokinetics of ofloxacin in healthy volunteers.

Authors:  J H Yuk; C H Nightingale; R Quintiliani; K R Sweeney
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

Review 7.  Clinical pharmacokinetics of newer cephalosporins.

Authors:  M E Klepser; M N Marangos; K B Patel; D P Nicolau; R Quintiliani; C H Nightingale
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

8.  Role of pharmacokinetics and pharmacodynamics in the design of dosage schedules for 12-h cefotaxime alone and in combination with other antibiotics.

Authors:  D E Nix; J J Schentag
Journal:  Diagn Microbiol Infect Dis       Date:  1995 May-Jun       Impact factor: 2.803

9.  Potential impact of quantitative susceptibility tests on the design of aminoglycoside dosing regimens.

Authors:  J P McCormack; J J Schentag
Journal:  Drug Intell Clin Pharm       Date:  1987-02

10.  Pharmacokinetic determinants of penicillin cure of gonococcal urethritis.

Authors:  H W Jaffe; A L Schroeter; G H Reynolds; A A Zaidi; J E Martin; J D Thayer
Journal:  Antimicrob Agents Chemother       Date:  1979-04       Impact factor: 5.191

View more
  10 in total

1.  Building and evaluation of a structured representation of pharmacokinetics information presented in SPCs: from existing conceptual views of pharmacokinetics associated with natural language processing to object-oriented design.

Authors:  Catherine Duclos-Cartolano; Alain Venot
Journal:  J Am Med Inform Assoc       Date:  2003-01-28       Impact factor: 4.497

Review 2.  Once-daily administration of antiretrovirals: pharmacokinetics of emerging therapies.

Authors:  Anne-Marie Taburet; Sabine Paci-Bonaventure; Gilles Peytavin; Jean-Michel Molina
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 3.  Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC.

Authors:  Markus Mueller; Amparo de la Peña; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

4.  Relevance of antibacterial distribution: the particular case of bone penetration.

Authors:  Amparo Sánchez Navarro
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

5.  Pharmacokinetics of ciprofloxacin as a tool to optimise dosage schedules in community patients.

Authors:  M Dolores Sánchez Navarro; Carlos Coloma Milano; Aránzazu Zarzuelo Castañeda; M Luisa Sayalero Marinero; Amparo Sánchez-Navarro
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 6.  Antimicrobial treatment of febrile neutropenia: pharmacokinetic-pharmacodynamic considerations.

Authors:  Tiphaine Goulenok; Bruno Fantin
Journal:  Clin Pharmacokinet       Date:  2013-10       Impact factor: 6.447

7.  Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients.

Authors:  Maria del Mar Fernández de Gatta Garcia; Natalia Revilla; Maria Victoria Calvo; Alfonso Domínguez-Gil; Amparo Sánchez Navarro
Journal:  Intensive Care Med       Date:  2006-12-13       Impact factor: 17.440

Review 8.  A retrospective analysis of pharmacokinetic-pharmacodynamic parameters as indicators of the clinical efficacy of ceftizoxime.

Authors:  A Sánchez-Navarro; C I Colino; M M Sánchez Recio
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 9.  Selecting antibacterials for outpatient parenteral antimicrobial therapy : pharmacokinetic-pharmacodynamic considerations.

Authors:  Richard S Slavik; Peter J Jewesson
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

10.  Pharmacokinetic/pharmacodynamic evaluation of antimicrobial treatments of orofacial odontogenic infections.

Authors:  Arantxa Isla; Andrés Canut; Alicia R Gascón; Alicia Labora; Bruno Ardanza-Trevijano; Maria Angelés Solinís; Jose Luis Pedraz
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.